8-K: Acurx Pharmaceuticals Announces Fourth Quarter and Full Year 2024 Results, Highlights Ibezapolstat's Progress

Acurx Pharmaceuticals reported its Q4 and full year 2024 financial results, emphasizing positive clinical data and regulatory advancements for its lead antibiotic candidate, ibezapolstat.

Summary

• Acurx Pharmaceuticals announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company highlighted positive clinical data from Phase 2 trials of ibezapolstat, showing a 96% clinical cure rate in patients with CDI.
• 100% of ibezapolstat-treated patients who achieved clinical cure remained cured one month after treatment, compared to 86% for vancomycin.
• The company closed a $2.5 million registered direct offering in January 2025 and another offering in March 2025 raising $1.1 million.
• Acurx received positive regulatory guidance from the EMA for the ibezapolstat Phase 3 clinical trial program.
• The company ended the year with $3.7 million in cash, compared to $7.5 million at the end of 2023.
• Research and development expenses for 2024 were $5.4 million, a decrease from $6.0 million in 2023.
• The net loss for 2024 was $14.1 million, or $0.87 per share, compared to a net loss of $14.6 million, or $1.15 per share, in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook due to promising clinical trial results and regulatory advancements. However, the decreased cash position and ongoing net losses temper the overall sentiment.

Positives

• High clinical cure rates were observed with ibezapolstat in Phase 2 trials.
• Positive regulatory guidance from the EMA supports the Phase 3 clinical trial program.
• New publications support the potential of ibezapolstat to restore the gut microbiome.
• A new Japanese patent strengthens the company's intellectual property position.
• The company successfully raised capital through registered direct offerings.
• R&D expenses decreased year-over-year.

Negatives

• The company experienced a net loss of $14.1 million for the year ended December 31, 2024.
• Cash reserves decreased from $7.5 million at the end of 2023 to $3.7 million at the end of 2024.

Risks

• The company's future success depends on the successful completion of Phase 3 clinical trials for ibezapolstat.
• Regulatory approval is not guaranteed, even with positive clinical trial results.
• The company may need to raise additional capital to fund its operations.
• The company faces competition from other companies developing treatments for CDI.

Future Outlook

Acurx plans to commence its international Phase 3 registration program for ibezapolstat. The company is also focused on the ongoing development of ACX-375C, its pre-clinical antibiotic candidate.

Management Comments

• These exciting results demonstrate two properties of ibezapolstat which may contribute to its anti-recurrence effect.
• First, the preservation and restoration of beneficial bacterial classes in the gut provide resistance to recolonization by C. difficile.
• Second, these data, presented for the first time, indicate that these beneficial bacteria known to metabolize primary to secondary bile acids persist in ibezapolstat-treated patients providing another important mechanism to prevent recurrent CDI
• With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program.
• Were hopeful that this anti-recurrence effect of IBZ could mitigate the need for expensive microbiome therapeutic agents to prevent recurrent CDI.

Industry Context

Acurx is developing ibezapolstat to address the urgent threat of C. difficile infection (CDI), as designated by the CDC. The company aims to provide a more selective antibiotic that preserves the gut microbiome, potentially reducing recurrence rates compared to existing treatments like vancomycin and metronidazole. The positive EMA guidance and Phase 2 results position Acurx to compete in the market for CDI treatments.

Comparison to Industry Standards

• The 96% clinical cure rate observed in Acurx's Phase 2 trials for ibezapolstat is competitive with existing treatments for CDI.
• Vancomycin, a commonly used antibiotic for CDI, has shown varying cure rates in clinical trials, typically ranging from 70% to 90%.
• Fidaxomicin, another antibiotic used for CDI, has demonstrated higher cure rates than vancomycin in some studies, but it is also more expensive.
• Acurx's focus on preserving the gut microbiome with ibezapolstat aligns with the growing recognition of the importance of microbiome health in preventing recurrent CDI.
• Companies like Seres Therapeutics are developing microbiome-based therapeutics to prevent recurrent CDI, which could be complementary to ibezapolstat if it receives approval.

Stakeholder Impact

• Shareholders: The positive clinical data and regulatory progress could increase shareholder value.
• Patients: Ibezapolstat has the potential to provide a more effective treatment option for CDI.
• Employees: The company's progress could lead to job security and growth opportunities.
• Creditors: The company's financial stability is important for meeting its obligations.

Next Steps

• Commence international Phase 3 registration program for ibezapolstat.
• Continue development of ACX-375C, the pre-clinical antibiotic candidate.
• File a Marketing Authorization Application with the EMA after successful completion of Phase 3 clinical trials.

Key Dates